GMO’s 2025 year-end letter argues that the valuation gap between value and growth remains near historic extremes, sustaining the opportunity set for its market-neutral Equity Dislocation strategy
-
The strategy returned 15.8% gross (13.4% net) in 2025 and 69.3% gross since inception, despite no meaningful narrowing in value/growth spreads.
-
U.S. value sits near the 4th percentile of relative valuation; value would need to outperform growth by ~70% in the U.S. (50% globally) to revert to median levels.
-
Negative beta characteristics (-0.18 vs MSCI ACWI) and strong short alpha—particularly in speculative tech—reinforce diversification appeal.
Is speculative excess the catalyst—or merely the fuel—for eventual mean reversion? The full letter details positioning.
To read this article, you need a subscription to Investment Officer. If you don't have a subscription yet, click on 'Subscribe' to see the various subscription options.
